- Eli Lilly's recombinant human insulin analog, Humalog (insulin lispro) has been launched in Switzerland, its first market. The drug has also been cleared for marketing in South Africa, Lithuania and Russia (it has not yet been launched in Russia despite reports to the contrary; Marketletter January 29). The European Committee on Proprietary Medicinal Products has issued a positive recommendation on the product, and it is due for appraisal in the USA at the end of this month. It is the first insulin analog to be launched in the world, and offers improved glucose control to regular insulin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze